Siemens Healthineers reports steady growth in Q2 2024 By Investing.com

Siemens Healthineers AG (SHL.DE) has reported a 3% revenue growth in Q2 2024, aligning with market expectations, and a 13% increase in adjusted earnings per share (EPS) to EUR 0.55.

The company has seen expansion across its key segments and remains committed to achieving its future growth targets, with expectations of 6-8% comparable revenue growth and 12-15% EPS growth.

Key Takeaways

• Siemens Healthineers reports 3% revenue growth and a 13% rise in adjusted EPS to EUR 0.55 in Q2 2024.
• The company has seen growth in Imaging, Varian, Advanced Therapies, and Diagnostics segments.
• Siemens Healthineers expects to meet its growth targets of 6-8% revenue growth and 12-15% EPS growth.
• The company highlighted its focus on creating value through innovation and expanding access to healthcare.
• A strong book-to-bill ratio of 1.08 in Q2, with expectations to remain above 1.1 for the fiscal year.
• Siemens Healthineers is confident in its outlook for China, expecting improvement in the second half of the year.

Company Outlook

• Siemens Healthineers confirms its outlook for fiscal year 2024.
• The company is on track to meet its growth targets, with a focus on efficient operations and better diagnosis and treatment solutions.
• Siemens Healthineers expects backswing growth in China and margin expansion in key segments.
• Revenue growth in EMEA and Asia Pacific has been positive.

Bearish Highlights

• Imaging is expected to end the fiscal year in the lower half of its revenue and margin range.
• Higher tax rates are anticipated in the second half of the year compared to the first half.

Bullish Highlights

• Varian is expected to drive revenue growth in Imaging in the current quarter.
• Margin improvement in Imaging is expected in the second half of the year.
• The MAGNETOM.Flow MRI system, part of the helium-free MRI program, is being introduced step-by-step.
• The company has seen strong value partnerships and is the better company in the industry.

Misses

• No significant changes in pricing or central procurement of imaging devices have been observed in China.

Q&A Highlights

• The company addressed the underlying growth in China’s healthcare sector and the impact of the anticorruption campaign and stimulus programs.
• Siemens Healthineers is making progress in in-sourcing components for Varian systems and is working on cost reduction projects.
• The company is satisfied with the performance and decisions made in the area of…